Last reviewed · How we verify
NCT05393024
Patient With MMRR Treated With Belantamab Mafotidine on Monotherapy
trial testing Belantamab mafodotin in Multiple Myeloma in 78 participants. Completed in 12 August 2024.
12 August 2024
Quick facts
| Lead sponsor | Fondazione EMN Italy Onlus |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 78 |
| Start date | 22 July 2022 |
| Primary completion | 12 August 2024 |
| Estimated completion | 12 August 2024 |
| Sites | 10 locations across Italy |
Drugs / interventions tested
- Belantamab mafodotin (BELANTAMAB MAFODOTIN) — full drug profile →
Conditions studied
- Multiple Myeloma — all drugs for Multiple Myeloma →
Sponsor
Fondazione EMN Italy Onlus — full company profile →
Who can join
18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a retrospective/prospective observational study evaluating the efficacy and safety of Belantamab Mafotidin as a single agent in patients with Multiple Myeloma Relapse/Refractory (MMRR) treated in clinical pratice under compassionate use
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05393024
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Belantamab mafodotin
Trials testing the same drug.
- NCT07224672 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, an · Phase 2 · not yet recruiting
- NCT07227311 — A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants · Phase 2 · not yet recruiting
- NCT06679101 — A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab · Phase 3 · recruiting
- NCT05922501 — Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT05714839 — A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monother · Phase 1, PHASE2 · recruiting
Other recruiting trials for Multiple Myeloma
Currently open trials in the same condition.
- NCT07200102 — Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma · Phase 1 · recruiting
- NCT07340853 — CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma · Phase 1 · recruiting
- NCT07454382 — A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma · Phase 2 · recruiting
- NCT07266441 — A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma · Phase 2 · recruiting
- NCT07258511 — A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With · Phase 3 · recruiting
Other Fondazione EMN Italy Onlus trials
Trials by the same sponsor.
- NCT06682637 — Melflufen for Elderly Patients With Relapsed Myeloma · Phase 2 · withdrawn
- NCT05001087 — A "Physician & Patient-powered" Cohort Registry (MY MYELOMA) · recruiting
- NCT04124497 — A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients · Phase 2 · active not recruiting
- NCT04096066 — A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant · Phase 3 · active not recruiting
- NCT03440411 — Pom-dex Versus Pom-Cyclo-dex in MM Patients With Biochemical or Clinical Relapse, During Lena Maintenance Treatment · Phase 3 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05393024 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fondazione EMN Italy Onlus
- Last refreshed: 15 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05393024.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing